Sun Pharma announces positive phase-3 data for psoriasis dru
Sun Pharmaceutical Industries Ltd on Wednesday said two pivotal phase-3 clinical trials evaluating the efficacy and safety of the investigational anti-plaque psoriasis drug tildrakizumab have met their primary endpoints. Tildrakizumab (MK-3222) is a monoclonal antibody that selectively blocks the cytokine IL-23, which causes inflammation in patients with moderate-to-severe plaque psoriasis, a chronic immune disease that affects the skin. The randomized, placebo-controlled, multicentre studies have found tildrakizumab safe and effective in moderate-to-severe plaque psoriasis compared to a placebo and comparative drug etanercept.
Read more: http://www.livemint.com/Industry/eHxVmwpRqTbBVRw37HCeWJ/Sun-Pharma-announces-positive-phase3-data-for-psoriasis-dru.html
Dr. M●●●●●●d I●●●r and 4 others like this
Like
Comment
Share